What do systematic reviews say?

Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ self‐selected music vs no music

The review found no eligible studies for this question.

• Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs self‐selected music

The review found no eligible studies for this question.

• Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Very low

Motivational interventions to improve adherence to airway clearance treatment for people with CF ‐ specifically‐composed music vs no music

The review found no eligible studies for this question.

• Interventions for improving adherence to airway clearance treatment and exercise in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Standard rhGH vs no treatment

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 57 participants
  Very low

Digital technology vs usual care

Digital technology showed no clear difference in qoL: change from baseline in CFQ‐R score compared with usual care (moderate certainty).

• Digital technology for early identification of exacerbations in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Moderate

Avalglucosidase alfa vs alglucosidase alfa

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Low

Summary of findings: inhaled antioxidants vs placebo

• Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 153 participants
  Moderate

Vitamin D vs placebo

• Vitamin D supplementation for sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Low

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Summary of findings table ‐ Emicizumab prophylaxis vs on‐demand therapy

• Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Low

Summary of findings table ‐ Fitusiran prophylaxis vs on‐demand therapy

• Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 48 participants
  Low

Cipaglucosidase plus miglustat vs alglucosidase alfa plus placebo

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 121 participants
  Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1061 participants
  Moderate

Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 324 participants
  Low

Summary of findings ‐ Inhaled mannitol vs dornase alfa

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Summary of findings ‐ Inhaled mannitol plus dornase alfa vs dornase alfa

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Very low

Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)

• Inhaled mannitol for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  391 participants
  Very low